Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.

MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients. Because of limitations in current NAFLD treatment therapies, many new efforts focus on exploring non-pharmacologic means for managing the disease and in particular through dietary substances or bioactive phytochemicals in fruits, vegetables, and plants or their products. MAST4HEALTH aims at exploring the effect of Mastiha, a natural product of Greece which was recently shown to possess antioxidant/anti-inflammatory and lipid lowering properties. We designed a multicenter randomized double blind placebo controlled (parallel arm) clinical trial to test the effectiveness of Mastiha supplement as new non-pharmacologic strategy for NAFLD/NASH treatment. MAST4HEALTH will explore gene-diet interactions, more specifically the potential personalized activity of the Mastiha, and correlate genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post-intervention. The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers of the disease. To this end, MAST4HEALTH will train a number of researchers and PhD students in multidisciplinary approaches of this survey. MAST4HEALTH is expected to build and enhance cooperation among partners meanwhile strengthening the interaction between our academic and non-academic sectors

EARLY project aims to reduce the burden of non-communicable diseases such as mental health conditions (MHC), especially depression, anxiety, stress disorders, substance use disorders and identify and reduce risky modifiable exposures for these conditions in youth. EARLY will pursue this goal through developing a comprehensive exposure matrix which can be adapted to emerging new risks, to understand youth, parents`, and stakeholders perceptions, we will conduct qualitative, interviews, by providing representative, multinational data on youth MHC and through developing, implementing and evaluating a multicomponent intervention. This will serve as an innovative model for promoting mental health and preventing MHC. EARLY is a mixed methods study which combines qualitative and quantitative methods. To provide a overview on youth mental health measures we will review measures, to provide data on exposure factors and whether exposure estimates vary by country, age, and gender, we will review studies and identify and merge available data on youth mental health; to provide insights on perceptions we will conduct focus groups with end-users. To provide representative data on youth MHC we will conduct a cross-sectional survey which are the baseline data for the multicomponent pilot intervention in five selected countries. To provide data on effectiveness and sustainability of interventions to reduce MHC we will conduct a multicomponent intervention. The results will be a a) model of youth mental health, b) a matrix of exposures, c) insights and understandings on end-users perceptions of youth mental health, d) knowledge on services for use in the European region and identification of needs; e) representative data on youth mental health which can be easily accessed by researchers and policymakers; f) data on effectiveness and sustainability of interventions to reduce both exposures and MHC in youth and finally g) non-communicable diseases risk reduction in adolescence and youth.

VALESOR aims to make major contributions to the scientific and policy efforts to accommodate economic values of environmental stressors more homogenously in policy making, planning. The environmental stressors of concern for VALESOR are chemical stressors such as chemicals and air pollutants transmitted via air, water, and soil vectors. VALESOR will develop an innovative website tool for stakeholders to assess health and economic consequences of planned variations in chemical stressors. This website tool will be able to evolve: by given the fact that, at a given date, exposure and impact assessment of some chemical stressors would be still incomplete, thus providing partial and provisional assessment based on credible hypothesis. VALESOR will also engage in substantial outreach activities to promote the consideration of environmental stressors in economic decision making and to facilitate an establishment of a trans-disciplinary consistency in values used when valuing environmental stressors.VALESOR will previously develop a state-of-the-art environmental economic model which will be as complete as theoretically possible in its representation of economic values of pollution. In particular, VALESOR will increase the number of human health endpoints considered in economic welfare assessments of chemical and air pollution in connection with recent results and current projects. Based on earlier research and engagement with other programs, VALESOR will clarify which input knowledge is important prior to calculating economic values associated with pollution. In particular, VALESOR will benefit from the experience and knowhow of several of its partners who have already worked models and / or tools targeting air pollution. VALESOR will make concrete guidance with respect to how key economic wellbeing values should be used by policy makers